MxEP hat Vereinbarungen getroffen, um seine Investition in Swixx auf bis zu EUR 90 Millionen zu erhöhen, basierend auf der Erreichung bestimmter Ziele, auf Neudeutsch «milestones» genannt.
Swixx betreibt eigene Tochtergesellschaften in Zentral- und Osteuropa, Griechenland und Russland. Mit 600 Mitarbeitern und einem Umsatz von über 260 Millionen Euro im Jahr 2021. MxEP ist eine AMF-akkreditierte Managementgesellschaft, die sich auf Aktieninvestitionen im Gesundheits- und Ernährungssektor spezialisiert hat und derzeit ein Vermögen von über 1 Milliarde Euro verwaltet.
Team von Walder Wyss
Bei dieser Transaktion wurde das Team von Walder Wyss von Markus Vischer (Partner, Corporate/M&A, Teamleiter) und Nico Bernhard (Senior Associate, Corporate/M&A) geleitet und umfasste ferner Timon Nydegger und Michael Kissling (beide Associates Corporate/M&A).
Mitteilung der Swixx Biopharma AG über die Transaktion
Die Swixx Biopharma AG verkündet Folgendes über die Transaktion:
«Swixx Biopharma AG of Baar, Switzerland announced the signature of an investment agreement with Mérieux Equity Partners(MxEP) of Lyon, France whereby MxEP will invest €40 million into Swixx, taking a minority position. In addition, HBM Healthcare Investments (HBM) of Zug, Switzerland, who had invested in Swixx in 2017, will co-invest alongside Mérieux, increasing HBM’s investment in Swixx by €5 million. HBM’s and MxEP’s investments should close during the next few months, depending upon completion of routine regulatory approvals.
The new capital will be used to leverage the steady growth that Swixx has enjoyed over the past few years. MxEP has arrangements in place to increase its investment in Swixx up to €90 million, based upon the realisation of certain milestones. MxEP’s Managing Partner Benoît Chastaing will join Swixx’s Board. “It is a great pleasure to welcome Mérieux Equity Partners,” commented Swixx co-founder Michael Seeley.
“We are honoured that such a well-regarded healthcare fund as MxEP has seen fit to invest in Swixx. The Mérieux family’s long history of scientific innovation speaks for itself, and we feel privileged to be associated with such a partner. It’s my hope that Swixx, bolstered with this new infusion of €45 million cumulatively in growth capital, will be able to access even more new opportunities in acquisitions, licensing, and portfolio expansion. We look forward to work together with Benoît and his team.”
“We are delighted to partner with Swixx’s management team, founders and HBM,” said Benoît Chastaing, Managing Partner at MxEP. “We look forward to support the company in its next development phase. We have been impressed by how quickly Swixx has established itself as a reputable partner for biopharma clients based upon the highest standards of professionalism, knowledge and service. Mérieux aims to deploy its own expertise and industrial network to support Swixx’s future growth.” Barclays Bank PLC, acting through its investment bank (Barclays) acted as financial advisor and Walder Wyss AG (Zurich) acted as legal advisor to Swixx.
In turn, Rothschilds & Co acted as financial adviser and Baker McKenzie (Zurich) acted as legal advisor to MxEP.
About Swixx Biopharma AG
Swixx operates fully owned subsidiaries across Central and Eastern Europe, Greece, and Russia. With 600 employees and sales exceeding €260 million in 2021, Swixx has swiftly evolved into the largest and fastest-growing dedicated commercialization platform for biopharma and self-medication innovative companies in CEE. The company has gathered outstanding rare disease, oncology[1]haematology, specialty, and self-medication talent under one roof. For more information about Swixx, please visit: www.swixxbiopharma.com
About Mérieux Equity Partners
Mérieux Equity Partners („MxEP“) is an AMF-accredited management company dedicated to equity investments in the health and nutrition sector. MxEP actively supports entrepreneurs and companies with differentiated products and services, giving them privileged access to its sector expertise and international network. MxEP currently manages over €1 billion in assets and has just launched its fifth vehicle – dedicated to growth capital/LBO investments – with a target size of €500 million. For further information about MxEP, please visit: www.merieux-partners.com
About HBM Healthcare Investments
HBM Healthcare Investments actively invests in the human medicine, biotechnology, medical technology and diagnostics sectors and related areas. The company holds and manages an international portfolio of promising companies. Many of these companies have their lead products already available on the market or at an advanced stage of development. The portfolio companies are closely tracked and actively guided on their strategic directions. HBM Healthcare Investments has an international shareholder base and is listed on SIX Swiss Exchange (ticker: HBMN). For further information about HBM, please visit: www.hbmhealthcare.com/en »
